4-(1-(4-Bromophenyl)piperidin-4-yl)morpholine → 4-(4-Morpholinopiperidin-1-yl)phenylboronic acid

HRID 447455Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 447455
C(N1[CH2:9][CH2:8][N:7]([C:10]2[CH:15]=[CH:14][C:13]([B:16]([OH:18])[OH:17])=[CH:12][CH:11]=2)[CH2:6][CH2:5]1)(C)C.BrC1C=CC(N2CC[CH:29]([N:32]3[CH2:37][CH2:36][O:35][CH2:34][CH2:33]3)CC2)=CC=1>>[O:35]1[CH2:36][CH2:37][N:32]([CH:29]2[CH2:5][CH2:6][N:7]([C:10]3[CH:11]=[CH:12][C:13]([B:16]([OH:17])[OH:18])=[CH:14][CH:15]=3)[CH2:8][CH2:9]2)[CH2:33][CH2:34]1

Komponenten

3

Versuchsvorschrift

The title compound was synthesized according to the synthesis of 4-(4-isopropylpiperazin-1-yl)phenylboronic acid, except substituting 4-(1-(4-bromophenyl)piperidin-4-yl)morpholine (250 mg, 0.77 mmol). The aqueous layer was washed with EtOAc and concentrated. The residue was triturated with THF and the filtrate was concentrated to give the title compound as a yellow solid (87 mg, 40%). 1H NMR (400 MHz, MeOD) δ 7.58 (br s, 2H), 6.93 (d, J=7.5 Hz, 2H), 3.85-3.82 (m, 2H), 3.72 (br s, 4H), 2.72 (t, J=12.3 Hz, 2H), 2.63 (br s, 4H), 2.40-2.34 (m, 1H), 2.01-1.98 (m, 2H), 1.62-1.54 (m, 2H); MS ESI 291.1 [M+H]+, calcd for [C15H23BN2O3+H]+ 291.18.

Aufarbeitung

  1. customThe title compound was synthesized
  2. washThe aqueous layer was washed with EtOAc
  3. concentrationconcentrated
  4. customThe residue was triturated with THF
  5. concentrationthe filtrate was concentrated

Quellen und Nachweise

ORD-Eintrag
ord-3c3b6b88c5444628af31c7a065366a1c
Quelldatensatz
uspto-grants-2013_07
Patentnummer
US08481525B2

Notizen zur Reaktion

Wird geladen…